ClinicalTrials.gg
CompletedNCT04608396MERITUpdated Jul 12, 2022

Mechanistic Evaluation of Response in TRD (MERIT)

A Phase 2 interventional study of AXS-05 and Placebo in Treatment Resistant Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2022.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
87th of 181
44 · median 38
Started
2020
with 14 others
Phase 2
52 of 204
8 open now
Registered
113th of 204
by date
Lead sponsor
5 of 204
Axsome Therapeutics, Inc.

Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 87th largest by enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 52 in phase 2, and was the 113th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD).

This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in delaying relapse of depressive symptoms in patients with TRD who are in stable remission after treatment with AXS-05.

03

Conditions studied

  • Treatment Resistant Depression
  • Major Depressive Disorder

Keywords

  • AXS-05
  • Treatment Resistant Depression
  • TRD
  • NMDA receptor
  • Refractory depression
  • Resistant depression
  • Depression
  • Major depression
  • Relapse prevention
  • Dextromethorphan
  • Bupropion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Eligibility Criteria:

  • Ongoing symptoms of depression despite receiving treatment with two or more prior antidepressants during the current major depressive episode, prior to receiving AXS-05
  • Agree to use adequate method of for the duration of the study
  • Additional criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    AXS-05

    Drug: AXS-05

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAXS-05

    AXS-05 taken daily for up to 52 weeks, until relapse.

  • DrugPlacebo

    Placebo taken daily for up to 52 weeks, until relapse.

06

What researchers measure

Primary outcomes

  1. Relapse

    Assessed by clinician-rated scales.

    Time frame: Time from randomization to first relapse (up to 52 weeks)

07

Study locations

20 sites
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site
    Redlands, California 92374, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Miami, Florida 33122, United States
  • Clinical Research Site
    North Miami, Florida 33161, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Chicago, Illinois 606346, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Rochester, New York 14618, United States
  • Clinical Research Site
    Staten Island, New York 10312, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Raleigh, North Carolina 27609, United States
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Dallas, Texas 75243, United States
  • Clinical Research Site
    Houston, Texas 77058, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2021, 11 months.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2020
First posted
Oct 29, 2020
StartActual
Aug 13, 2020
Primary completionActual
Jul 30, 2021
CompletionActual
Jul 30, 2021
Results delay requested
Jul 8, 2022
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04608396
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Aug 13, 2020
Primary completion
Jul 30, 2021
Completion
Jul 30, 2021
Last update
Jul 12, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion